Press archive
The 20 recent news
11/19/09, Xarelto Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE more
11/11/09, Worldnews Improving the care of people with diabetes Primary and secondary prevention of diabetes / Focusing on self-care, environment, nutrition, therapy, and exercise more
11/11/09, Company Healthcare: Fight against Neglected Diseases As part of its societal responsibilities, Bayer HealthCare puts special emphasis on therapies for the so-called neglected diseases. More than 3.3 billion people, half of the world’s population,... more
11/11/09, Company Self-determined Family planning: worldwide initiative for maternal health and against child mortality A new Bayer HealthCare initiative with the motto “Family planning” will concentrate the company’s activities in developing countries, which have been running for 40 years now, and e... more
11/11/09, Company Data and Facts: “Family planning” Pregnancies Out of an estimated 210 million pregnancies per year world-wide, 38% are unplanned and about 20% end in abortion. The overwhelming majority of these abortions occur in developing countrie... more
10/29/09, Stories Geri Winkler and the Turquoise Goddess Diabetic climbs Cho Oyu, the sixth-highest mountain on Earth (8,201 meters) more
10/28/09, Bayer Schering Pharma Association of German Medical Journalists (VDMJ) and Bayer HealthCare honor good medical reporting European Journalists’ Prize 2009 announced more
10/27/09, Company Bayer back on the uptrend HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million ... more
10/23/09, Nexavar Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer Berlin, October 23, 2009 – Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Ne... more
10/22/09, Thrombosis The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market Berlin, October 22, 2009 – The Swiss regulatory authority Swissmedic has conducted an analysis with its expert medical committee on the latest data and studies regarding the risk of venous thro... more
10/08/09, Research & Development Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease Florbetaben will be used for the very first time in Alzheimer´s patients being treated with a vaccination therapy more
10/05/09, Qlaira Bayer’s novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding Results also confirm significant improvement in blood iron levels more
09/30/09, Nexavar Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer Preliminary results require further analysis and interpretation more
09/28/09, Contour First blood glucose monitor with Plug & Play Diabetes Management Software Bright color display screen / Rechargeable battery / Instructive text messages in native languages / Based on Bayer’s trusted Contour technology more
09/28/09, Contour First blood glucose designed especially for children Helping kids to manage their diabetes / Based on Bayer’s trusted Contour technology more
09/23/09, Nexavar Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival First presentation of results at joint ECCO-ESMO congress in Berlin, Germany more
09/22/09, Thrombosis Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President Development of the novel anticoagulant rivaroxaban commended / Three research and development teams on shortlist more
09/22/09, Bayer Schering Pharma Bayer to supply WHO with a product for the combination therapy of African sleeping sickness New combination therapy added to the WHO's Essential Drug List more
09/22/09, Cancer Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009 more
09/17/09, Bayer HealthCare Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009 Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions more
